Elizabeth Maples, PA
Physician Assistant · Houston, TXNPI 1548298003
Payments from drug & device makers
Across 141 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$385
- Alkermes, Inc.$297
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$295
- AbbVie$293
- Otsuka America Pharmaceutical, Inc.$251
- Lundbeck LLC$204
- plus $854 from 10 others
What the payments were for
- Food & beverage$2,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 14 | $385 |
| Alkermes, Inc. | 17 | $297 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $295 |
| AbbVie | 20 | $293 |
| Otsuka America Pharmaceutical, Inc. | 20 | $251 |
| Lundbeck LLC | 11 | $204 |
| E.r. Squibb & Sons, L.L.C. | 10 | $179 |
| Vanda Pharmaceuticals Inc. | 9 | $175 |
| Axsome Therapeutics, Inc. | 9 | $154 |
| Johnson & Johnson(2 entities) | 7 | $132 |
| Teva Pharmaceuticals USA, Inc. | 7 | $108 |
| Tris Pharma Inc | 2 | $33 |
| Almatica Pharma LLC | 1 | $21 |
| Biogen | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$2,579 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,671 |
| Oxcarbazepine | 22 | $919 |
| Duloxetine Hcl | 40 | $610 |
| Quetiapine Fumarate | 24 | $484 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $413 |
| Trazodone Hcl | 41 | $404 |
| Clonazepam | 48 | $388 |
| Bupropion XlBupropion Hcl | 23 | $366 |
| Buspirone Hcl | 19 | $241 |
| Aripiprazole | 12 | $159 |
| Lamotrigine | 14 | $127 |
| Topiramate | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Other physician assistant in Houston
- Simone SteeleHouston$237K
- Amanda WilhiteHouston$207K
- Christina YazdaniHouston$72K
- Julie Huynh-LuHouston$64K
- Jennifer FalconeHouston$48K
- Jacqueline WeatherlyHouston$47K
- Samantha SalvatoraHouston$45K
- Virginia SchneiderHouston$43K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.